Focus Stocks
Is Novartis Reversing?
Published on Monday, 06 February 2012 09:46 Written by TradersHuddle Staff
New York, February 6th (TradersHuddle.com) - Shares of Novartis AG (NYSE:NVS) closed the trading
day higher by $0.07 or 0.12% from its previous close. Novartis' shares price action formed what is considered to be a
doji close, where the open and close prices are very close to each other, mainly signaling an indecision between buyers and sellers.
Novartis AG (NYSE:NVS) manufactures pharmaceutical and consumer healthcare products. The Company produces branded and generic pharmaceuticals for a number of uses like cardiovascular, respiratory and infectious diseases. The Basel, Switzerland based company also offers over the counter vision and animal health products.
Novartis' current stock range is defined by a trough, which marks calculated support at $54.07 and by a peak that marked the resistance point at $58.37. These levels are closely watched by traders managing their positions.
Traders wanting to establish a position in Novartis or traders that are already holding the stock can use the doji close to their advantage, since the pattern present a short term pause in the stock's price action. This pause results in an entry point for traders depending of which way the stock resolves this short term indecision.
Doji are important candlesticks that provide information on their own and as components in a number of important patterns. Doji form when a security's open and close are virtually equal. The length of the upper and lower shadows can vary and the resulting candlestick looks like a cross, inverted cross or plus sign. Alone, doji are neutral patterns.
Any bullish or bearish bias is based on preceding price action and future confirmation. In the case of Novartis, given that the stock finished the session higher, bulls should monitor their positions for confirmation that stock will continue higher by taking today's intraday high. Below a Doji illustration:

Related Articles
- New Ratings: NVS, SNY, CYS
- Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
- Bulls taking Control of Novartis?
- Bulls and Bears on the Trenches of Novartis
- Bears Appeared on Novartis
- Bulls and Bears on the Trenches of Novartis
- Novartis Higher With High Volume
Related Partner Headlines
- Novartis AG ADR (NVS): Today's Featured Health Care Loser - TheStreet.com
- Novartis AG ADR (NVS): Today's Featured Health Care Loser - TheStreet.com
- Novartis Stock To Go Ex-dividend Monday (NVS) - TheStreet.com
- UPDATE: Bank of America Downgrades Novartis to Underperform - Benzinga
- From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery - Benzinga
- Novartis AG (NVS): Today's Featured Health Care Winner - TheStreet.com
- Novartis AG (NVS): Today's Featured Drugs Loser - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com -
Market Preview: Low-Grade Uncertainty - TheStreet.com -
The EPA's Dangerous Game - TheStreet.com -
Sticking with the Preferred Plan - TheStreet.com -
Infoblox Posts Blowout Earnings; Shares Rise - TheStreet.com -
Salesforce.com Inc. (CRM): Today's Featured Computer Software & Services Loser - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
SCVBank Elects Scott K. Rushing as New Chairman -
Heritage Oaks Bancorp to Pay Trust Preferred Interest and Accumulated TARP Dividends -
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012 -
Diamond Value Management strategy and corporate turnaround leverages Rockwell repositioning -
Verizon Singapore Lauded for Its Sustainability Efforts -
Photo Release -- Cars For a Living: The World's First High-Octane Business Podcast -
Internal Fixation Systems, Inc. Enters Into $7.5M Equity Purchase Agreement With Hyde Park Advisors, LLC, an Affiliate of Institutional Investor Central Park Financial









